Advertisement

Topics

Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP

2014-08-27 03:12:56 | BioPortfolio

Summary

This study aims to test the safety and efficacy of six new malaria vaccines - AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. These vaccines consist of inactivated viruses which have been modified − so they cannot reproduce (replicate) in humans, and also to include genetic material (genes) for malaria proteins which are expressed by the malaria parasite during both liver and blood stage infection. The vaccines are designed to stimulate an immune response to these malaria proteins (immunogenicity describes the nature and magnitude of this immune response) and thus provide protection against malaria infection. The protective efficacy of vaccines will be evaluated by challenging a small number of volunteers who have received the vaccines with malaria infection from the bites of infected mosquitos(sporozoite challenge).

Study Design

Allocation: Non-Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Conditions

Malaria

Intervention

AdCh63 MSP1, MVA MSP1, challenge, AdCh63 AMA1, MVA AMA1, challenge, AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge, AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge, Sporozoite challenge

Location

Hospital for Tropical Diseases Mortimer Market
London
United Kingdom
WC1E 6JB

Status

Not yet recruiting

Source

University of Oxford

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:12:56-0400

Clinical Trials [893 Associated Clinical Trials listed on BioPortfolio]

A Study of AdCh63 AMA1 Alone and With MVA AMA1

This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 AMA1, simian adenovirus encoding Plasmodium falciparum blood stage antigen, Apical Membrane Ant...

A Study of the Safety and Effectiveness of Two New Malaria Vaccines

This study aims to test the safety of two new malaria vaccines AdCh63 MSP1 and MVA MSP1. These vaccines consist of inactivated viruses which have been modified − so they cannot reproduce...

A Study of AdCh63 ME−TRAP Alone and With MVA ME−TRAP

This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 ME-TRAP, simian adenovirus encoding Plasmodium falciparum antigens. This follows promising phas...

Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant

The purpose of this study is to determine the safety of and immune response to a preventive malaria vaccine, MSP1 42-C1/Alhydrogel, in healthy adults. This study will also compare response...

Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine

This study will evaluate the safety and immune response of healthy volunteers to an experimental malaria vaccine called AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909. Malaria is a...

PubMed Articles [3594 Associated PubMed Articles listed on BioPortfolio]

Recombinant lactococcus lactis expressing Eimeria tenella AMA1 protein and its immunological effects against homologous challenge.

Avian coccidiosis leads to severe economic losses for the global poultry industry. Apical membrane antigen 1 (AMA1) of E. tenella (EtAMA1) plays a vital role during invasion of parasites into host cel...

First report of Anaplasma marginale infection in goats, Brazil.

Anaplasma marginale, the causative agent of bovine anaplasmosis, is a tick-borne bacterium that causes significant economic losses for cattle industries and is increasingly being detected in other ani...

Engineering Lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin.

Probiotic bacteria are being explored for the in situ delivery of various therapeutic agents. In this study, we aimed to express two HIV-inhibiting lectins, actinohivin (AH) and griffithsin (GRFT), in...

Influenza Challenge and the Challenge of Drug Development.

Challenge of the Mini-fluid Challenge: Filling Twice without Creating a Self-fulfilling Prophecy Design.

Medical and Biotech [MESH] Definitions

The organization, management, and assumption of risks of a business or enterprise, usually implying an element of change or challenge and a new opportunity.

Undertaking a task involving a challenge for achievement or a desirable goal in which there is a lack of certainty or a fear of failure. It may also include the exhibiting of certain behaviors whose outcomes may present a risk to the individual or to those associated with him or her.

A frequent complication of drug therapy for microbial infection. It may result from opportunistic colonization following immunosuppression by the primary pathogen and can be influenced by the time interval between infections, microbial physiology, or host resistance. Experimental challenge and in vitro models are sometimes used in virulence and infectivity studies.

More From BioPortfolio on "Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Malaria
Malaria is a serious tropical disease spread by mosquitoes. If malaria is not diagnosed and treated promptly, it can be fatal. What causes malaria? Malaria is caused by a type of parasite known as Plasmodium. There are many different types of Plasmod...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Searches Linking to this Trial